Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT04245722
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT04221477
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇩🇪Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany
Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT04169737
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 498
- Registration Number
- NCT04077723
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇪UZ Gent, Gent, Belgium
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Klinikum Stuttgart
- Target Recruit Count
- 4
- Registration Number
- NCT04073147
- Locations
- 🇩🇪
Klinikum Stuttgart, Stuttgart, Baden-Württemberg, Germany
A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Deok-Hwan Yang
- Target Recruit Count
- 31
- Registration Number
- NCT04059081
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT04034056
- Locations
- 🇮🇹
Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpigh, Bologna, Emilia-Romagna, Italy
🇮🇹Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Friuli-Venezia Giulia, Italy
FT516 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT04023071
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 50
- Registration Number
- NCT03980171
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Townsville Hospital and Health Services, Townsville, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile-Hemato-Oncology, Santiago, Metropolitana, Chile
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.